TY - JOUR
T1 - Alveolar ridge and maxillary sinus augmentation using rhBMP-2
T2 - A systematic review
AU - de Freitas, Rubens Moreno
AU - Spin-Neto, Rubens
AU - Junior, Elcio Marcantonio
AU - Pereira, Luís Antônio Violin Dias
AU - Wikesjö, Ulf Me
AU - Susin, Cristiano
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Purpose: The aim of this systematic review was to evaluate clinical and safety data for recombinant human bone morphogenetic protein-2 (rhBMP-2) in an absorbable collagen sponge (ACS) carrier when used for alveolar ridge/maxillary sinus augmentation in humans. Materials and Methods: Clinical studies/case series published 1980 through June 2012 using rhBMP-2/ACS were searched. Studies meeting the following criteria were considered eligible for inclusion: >10 subjects at baseline and maxillary sinus or alveolar ridge augmentation not concomitant with implant placement. Results: Seven of 69 publications were eligible for review. rhBMP-2/ACS yielded clinically meaningful bone formation for maxillary sinus augmentation that would allow placement of regular dental implants without consistent differences between rhBMP-2 concentrations. Nevertheless, the statistical analysis showed that sinus augmentation following autogenous bone graft was significantly greater (mean bone height: 1.6mm, 95% CI: 0.5-2.7mm) than for rhBMP-2/ACS (rhBMP-2 at 1.5mg/mL). In extraction sockets, rhBMP-2/ACS maintained alveolar ridge height while enhancing alveolar ridge width. Safety reports did not represent concerns for the proposed indications. Conclusions: rhBMP-2/ACS appears a promising alternative to autogenous bone grafts for alveolar ridge/maxillary sinus augmentation; dose and carrier optimization may expand its efficacy, use, and clinical application.
AB - Purpose: The aim of this systematic review was to evaluate clinical and safety data for recombinant human bone morphogenetic protein-2 (rhBMP-2) in an absorbable collagen sponge (ACS) carrier when used for alveolar ridge/maxillary sinus augmentation in humans. Materials and Methods: Clinical studies/case series published 1980 through June 2012 using rhBMP-2/ACS were searched. Studies meeting the following criteria were considered eligible for inclusion: >10 subjects at baseline and maxillary sinus or alveolar ridge augmentation not concomitant with implant placement. Results: Seven of 69 publications were eligible for review. rhBMP-2/ACS yielded clinically meaningful bone formation for maxillary sinus augmentation that would allow placement of regular dental implants without consistent differences between rhBMP-2 concentrations. Nevertheless, the statistical analysis showed that sinus augmentation following autogenous bone graft was significantly greater (mean bone height: 1.6mm, 95% CI: 0.5-2.7mm) than for rhBMP-2/ACS (rhBMP-2 at 1.5mg/mL). In extraction sockets, rhBMP-2/ACS maintained alveolar ridge height while enhancing alveolar ridge width. Safety reports did not represent concerns for the proposed indications. Conclusions: rhBMP-2/ACS appears a promising alternative to autogenous bone grafts for alveolar ridge/maxillary sinus augmentation; dose and carrier optimization may expand its efficacy, use, and clinical application.
KW - Alveolar ridge augmentation
KW - BMP
KW - Bone morphogenetic proteins
KW - Bone regeneration
KW - Maxillary sinus augmentation
UR - http://www.scopus.com/inward/record.url?scp=84885016348&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885016348&partnerID=8YFLogxK
U2 - 10.1111/cid.12156
DO - 10.1111/cid.12156
M3 - Article
AN - SCOPUS:84885016348
SN - 1523-0899
VL - 17
SP - e192-e201
JO - Clinical Implant Dentistry and Related Research
JF - Clinical Implant Dentistry and Related Research
IS - S1
ER -